Electrogene therapy using endostatin, with or without suicide gene therapy, suppresses murine mammary tumor growth and metastasis

Cancer Gene Therapy

Volumn 14, Issue 3, 2007, Pages 268-278

  Shibata, M A ^a   Morimoto, J ^a   Doi, H ^a   Morishima, S ^a   Naka, M ^a   Otsuki, Y ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiostasis; Electroporation; Mammary cancer; Metastasis; Suicide gene therapy

Indexed keywords

ENDOSTATIN; GANCICLOVIR; HERPESVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST METASTASIS; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DENSITY; DNA SYNTHESIS; ELECTROPORATION; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPH VESSEL; METASTASIS INHIBITION; MICROVASCULATURE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SUICIDE GENE; SUICIDE GENE THERAPY; TRANSGENIC MOUSE; TUMOR VOLUME;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BYSTANDER EFFECT; ELECTROPORATION; ENDOSTATINS; ENDOTHELIUM, VASCULAR; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; UMBILICAL VEINS;

MURINAE; MUS;

EID: 33847029169     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701009     Document Type: Article

References (49)

1. Kuroishi T, Tominaga S. Epidemiol. Breast Cancer. Jpn J Cancer Chemother 2001; 28: 168-173.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23-47.
3. Folkman J. Angiogenesis-dependent diseases. Semin Oncol 2001; 28: 536-542.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
5. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998; 95: 9064-9066.
6. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89: 1181-1194.
7. Folkman J. Endogenous angiogenesis inhibitors. Apmis 2004; 112: 496-507.
8. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al. Endostatin: an endogenous inhibitorof angiogenesis and tumorgr owth. Cell 1997; 88: 277-285.
9. Korpelainen EI, Alitalo K. Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998; 10: 159-164.
10. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci USA 2001; 98: 1024-1029.
11. Moolten I. Drug sensitivity ('suicide') genes for selective cancer therapy. Cancer Gene Ther 1994; 1: 107-112.
12. CulverKW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vectorproducer cells for treatment of experimental brain tumors. Science 1992; 256: 1550-1552.
13. Shibata MA, Morimoto J, Otsuki Y. Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther 2002; 9: 16-27.
14. Titomirov AV, Sukharev S, Kistanova E. In vivo electroporation and stable transformation of skin cells of newborn mice by plasmid DNA. Biochim Biophys Acta 1991; 1088: 131-134.
15. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16: 867-870.
16. Suzuki T, Shin B, Fujikura K, Matsuzaki T, Takata K. Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett 1998; 425: 436-440.
17. Harimoto K, Sugumura K, Lee C, Kuratsukuri K, Kishimoto T. In vivo gene transfer methods in the bladder without viral vectors. Br J Urol 1998; 81: 870-874.
18. Harrison R, Byrne BJ, Tung L. Electroporation-mediated gene transfer in cardiac tissue. FEBS Lett 1998; 435: 1-5.
19. Goto T, Nishi T, Tamura T, Dev SB, Takeshima H, Kochi M et al. Highly efficient electro-gene therapy of solid tumor by using an expression plasmid for the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 2000; 97: 354-359.
20. LohrF, Lo DY, Zaharoff DA, Hu K, Zhang X, Li Y et al. Effective tumorther apy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 2001; 61: 3281-3284.
21. Yamashita Y, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, Hamatsu T et al. Electroporation-mediated nterleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 2001; 61: 1005-1012.
22. Shibata MA, Horiguchi T, Morimoto J, Otsuki Y. Massive apoptotic cell death in chemically induced rat urinary bladdercar cinomas following in situ HSVtk electrogene transfer. J Gene Med 2003; 5: 219-231.
23. Shibata MA, Miwa Y, Miyashita M, Morimoto J, Abe H, Otsuki Y. Electrogene transfer of an Epstein-Barr virusbased plasmid replicon vector containing the diphtheria toxin A gene suppresses mammary carcinoma growth in SCID mice. Cancer Sci 2005; 96: 434-440.
24. Shibata MA, Ito Y, Morimoto J, Kusakabe K, Yoshinaka R, Otsuki Y. In vivo electrogene transfer of interleukin-12 inhibits tumorgr owth and lymph node and lung metastasis in mouse mammary carcinomas. J Gene Med 2006; 8: 335-352.
25. Morimoto J, Imai S, Haga S, Iwai Y, Iwai M, Hiroishi S et al. New murine mammary tumor cell lines. In vitro Cell Dev Biol 1991; 27A: 349-351.
26. Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumorgr owth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial- mediated apoptotic mechanism. Carcinogenesis 2004; 25: 1887-1898.
27. Shibata MA, Liu M-L, Knudson MC, Shibata E, Yoshidome K, Bandy T et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 1999; 18: 2692-2701.
28. Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K et al. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res 2000; 6: 1647-1654.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
30. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181-187.
31. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS et al. Endostatin blocks vascular endothelial growth factormediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002; 277: 27872-27879.
32. KiskerO, BeckerCM, Prox D, Fannon M, D'Amato R, Flynn E et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001; 61: 7669-7674.
33. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R et al. Tissue examination to monitorantiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001; 7: 3366-3374.
34. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21: 223-231.
35. Klatzmann D, Valery CA, Bensimon G, Marro B, Boyer O, Mokhtari K et al. A phase I/II study of herpes simplex virus type I thymidine kinase 'suicide' gene therapy for recurrent glioblastoma. Hum Gene Ther 1998; 9: 2595-2604.
36. Sterman DH, Treat J, Litzky LA, Amin KM, Coonrod L, Molnar-Kimbe K et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998; 9:1083-1092.
37. Shalev M, Kadmon D, Teh BS, Butler E, Aguilar-Cordova E, Thompson TC et al. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000; 163: 1747-1750.
38. Kuriyama S, Kikukawa M, Masui K, Okuda H, Nakatani T, Akahane T et al. Cancergene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumorcells in vivo. Int J Cancer 1999; 83: 374-380.
39. Shibata MA, Morimoto J, Ito Y, Kusakabe K, Otsuki Y. Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer. Med Electron Microsc 2004; 37: 216-224.
40. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002; 13: 155-168.
41. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ et al. Recombinant IL-12 administration induces tumor regression in association with IFN-g production. J Immunol 1994; 153: 1697-1706.
42. Uesato M, Gunji Y, Tomonaga T, Miyazaki S, Shiratori T, Matsubara H et al. Synergistic antitumor effect of antiangiogenic factorgenes on colon 26 produced by low-voltage electroporation. Cancer Gene Ther 2004; 11: 625-632.
43. Pulkkanen KJ, Laukkanen JM, Fuxe J, Kettunen MI, Rehn M, Kannasto JM et al. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther 2002; 9: 908-916.
44. Abdollahi A, Lipson KE, Sckell A, ZieherH, Klenke F, Poerschke D et al. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumoreffects. Cancer Res 2003; 63: 8890-8898.
45. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998; 153: 103-108.
46. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154: 1381-1390.
47. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 1995; 92: 3566-3570.
48. Brockstedt DG, Diagana M, Zhang Y, Tran K, Belmar N, MeierM et al. Development of anti-tumorimmunity against a non-immunogenic mammary carcinoma through in vivo somatic GM-CSF, IL-2, and HSVtk combination gene therapy. Mol Ther 2002; 6: 627-636.
49. Cichon T, Jamrozy L, Glogowska J, Missol-Kolka E, Szala S. Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther 2002; 9: 771-777.